Literature DB >> 23893456

Medical treatment of dystonia.

Joseph Jankovic1.   

Abstract

Medications such as anticholinergic drugs, dopamine modulators, baclofen, muscle relaxants, and other pharmacologic agents have been used for a long time to treat dystonia, but the introduction of botulinum toxin and deep brain stimulation clearly revolutionized the symptomatic treatment of this neurological movement disorder. Therapy of dystonia can be divided into the following categories: (1) physical, supportive, and ancillary therapy; (2) pharmacologic treatment; (3) chemodenervation with botulinum toxin; and (4) peripheral and central surgery (deep brain stimulation). Except in some cases of secondary dystonia, pathogenesis-targeted or disease-modifying therapy is currently not available. This review focuses on evidence-based medical treatment of dystonia, highlighting recent advances, with emphasis on individualized approach.
© 2013 Movement Disorder Society. © 2013 Movement Disorder Society.

Entities:  

Keywords:  baclofen; botulinum toxin; dystonia; tetrabenazine; trihexyphenidyl

Mesh:

Substances:

Year:  2013        PMID: 23893456     DOI: 10.1002/mds.25552

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

Review 1.  Treatment of dystonia.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 3.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 4.  Sensory aspects of movement disorders.

Authors:  Neepa Patel; Joseph Jankovic; Mark Hallett
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

Review 5.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

6.  Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.

Authors:  Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2017-08-20       Impact factor: 4.797

7.  Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.

Authors:  Rebecca Ahrens-Nicklas; Lars Schlotawa; Andrea Ballabio; Nicola Brunetti-Pierri; Mauricio De Castro; Thomas Dierks; Florian Eichler; Can Ficicioglu; Alan Finglas; Jutta Gaertner; Brian Kirmse; Joerg Klepper; Marcus Lee; Amber Olsen; Giancarlo Parenti; Arastoo Vossough; Adeline Vanderver; Laura A Adang
Journal:  Mol Genet Metab       Date:  2018-01-31       Impact factor: 4.797

Review 8.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

Review 9.  Update on treatments for dystonia.

Authors:  D Cristopher Bragg; Nutan Sharma
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

10.  Cholinergic mechanisms of high-frequency stimulation in entopeduncular nucleus.

Authors:  Feng Luo; Zelma H T Kiss
Journal:  J Neurophysiol       Date:  2015-09-02       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.